Tal I Arnon Selected Research

Histocompatibility Antigens Class I

6/2006	Reduced KIR2DL1 recognition of MHC class I molecules presenting phosphorylated peptides.
8/2004	MHC class I-independent recognition of NK-activating receptor KIR2DS4.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tal I Arnon Research Topics

Disease

9	Neoplasms (Cancer) 01/2015 - 01/2004
2	Infections 09/2011 - 05/2006
2	Human Influenza (Influenza) 05/2006 - 01/2004
2	Melanoma (Melanoma, Malignant) 08/2004 - 03/2002
1	Coinfection 07/2024
1	Inflammation (Inflammations) 01/2023
1	Arthritis (Polyarthritis) 01/2023
1	Hyperplasia 05/2008
1	Prostatic Neoplasms (Prostate Cancer) 05/2008
1	Virus Diseases (Viral Diseases) 06/2006
1	Ankylosing Spondylitis 07/2005
1	Carcinoma (Carcinomatosis) 06/2005

Drug/Important Bio-Agent (IBA)

3	AntigensIBA 01/2023 - 10/2006
3	LigandsIBA 05/2008 - 03/2002
3	Proteins (Proteins, Gene)FDA Link 05/2008 - 03/2002
2	Histocompatibility Antigens Class IIBA 06/2006 - 08/2004
1	AntibodiesIBA 07/2024
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2023
1	Interferon Regulatory FactorsIBA 01/2023
1	ChemokinesIBA 01/2023
1	Immunoglobulin G (IgG)IBA 05/2008
1	Natural Killer Cell ReceptorsIBA 05/2006
1	Green Fluorescent ProteinsIBA 05/2006
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 07/2005
1	Tumor Biomarkers (Tumor Markers)IBA 06/2005
1	human CD99 proteinIBA 07/2004
1	CEACAM1 ProteinIBA 03/2004
1	Hemagglutinins (Hemagglutinin)IBA 01/2004
1	Viral HemagglutininsIBA 01/2004

Therapy/Procedure

2	Therapeutics 01/2015 - 05/2008